In a landmark decision, the Bombay High Court granted Novartis AG an ad-interim injunction against Novarish Healthcare Private Limited for trademark infringement. Novartis successfully argued that Novarish’s use of the “NOVARISH” mark was deceptively similar to its well-known “NOVARTIS” trademark, leading to the court’s decision to protect Novartis’s intellectual property rights.
Read more about Novartis says No to NovarishTag: Novartis
Cancerous Battle: Novartis and NATCO clash over Eltrombopag
In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).
Read more about Cancerous Battle: Novartis and NATCO clash over EltrombopagProfiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents
Learn about the patent cliff and how Novartis’ heart failure drug Vymada (Entresto®) will expire its patent protection in 2023. Find out more about secondary patents that can extend market exclusivity of Entresto® until 2033.
Read more about Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary PatentsDelhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition Proceedings
In a recent decision, the Delhi High Court gave clarity about how amended claims during opposition proceedings have to be dealt with by the Controller...
Read more about Delhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition ProceedingsRecap 2021- Indian Patent Case Laws
In this post, we bring to you few Patent Cases decided by Indian Courts in the year 2021 Merck Sharp And Dohme Corp & ANR...
Read more about Recap 2021- Indian Patent Case LawsImportant Patent Case law – 2021
In this post, we bring to you Important Patent Cases decided by Indian Courts in year 2021 FMC Corporation & ANR. vs Natco Pharma Limited...
Read more about Important Patent Case law – 2021Latest Patent & Design Updates – January 2022 – Part 1
In this week's update on patents - India requests emergency meeting of WTO General Council to discuss patent waiver; RGNIIPM announces online advanced training program...
Read more about Latest Patent & Design Updates – January 2022 – Part 1In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other Technologies
During the last two days, two interesting articles addressing accessibility of medical products and methods were published. While one article in 'The Hindu' spoke about...
Read more about In Support of Prof. Arul Scaria on Compulsory Licensing for COVID Vaccines, Medicines, Diagnostics and other TechnologiesNovartis Case Review
This Post was first published on 15th May, 2013. NOVARTIS AG (APPELLANT) Vs. UNION OF INDIA & OTHERS (RESPONDENTS) Decided by the Supreme...
Read more about Novartis Case ReviewVoting Machine Patent, Delhi High Court restrains Natco, Samsung and Huawei settle patent dispute and more
“Indian elections and Patents on voting machines, Delhi High Court restrains Natco from manufacturing cancer drug, Samsung and Huawei end eight - year long...
Read more about Voting Machine Patent, Delhi High Court restrains Natco, Samsung and Huawei settle patent dispute and more